Business
Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate
Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy Expands Axsome’s pipeline with new Phase 3-stage esreboxetine product
About this update from Axsome Therapeutics, Inc.
[{"type":"text","content":"Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy\n Expands Axsome’s pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia Esreboxetine met primary endpoints in completed Pfizer Phase 3 and Phase 2 placebo-controlled clinical trials in fibromyalgia (p","length":408,"tagName":"div"}]